Imaging of tumor glucose utilization with positron emission tomography

Cancer and Metastasis Reviews

Volumn 27, Issue 4, 2008, Pages 545-554

  Buerkle, Andrea ^a   Weber, Wolfgang A ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cancer; Fluorodeoxyglucose; Glucose metabolism; Positron emission tomography

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; DICHLOROACETIC ACID; FLUORODEOXYGLUCOSE; GLUCOSE TRANSPORTER; HEXOKINASE; MYC PROTEIN; PROTEIN KINASE B; PROTEIN P53; RAS PROTEIN;

CANCER CHEMOTHERAPY; CANCER STAGING; CELL PROLIFERATION; DNA SYNTHESIS; DRUG UPTAKE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCOLYSIS; HUMAN; HYPOXIA; IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RNA SYNTHESIS; SIGNAL TRANSDUCTION; TUMOR;

FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 52549096463     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-008-9151-x     Document Type: Review

References (81)

1. B. D. Cheson B. Pfistner M. E. Juweid R. D. Gascoyne L. Specht S. J. Horning 2007 Revised response criteria for malignant lymphoma Journal of Clinical Oncology 25 579 586
2. IMV (2006). 2005/06 PET market summary report. IMV Medical Information Division: Des Plaines.
3. O. Warburg K. Posener E. Negelein 1924 Ueber den Stoffwechsel von Tumoren Biochemische Zeitschrift 152 319 344
4. J. Czernin M. Allen-Auerbach H. R. Schelbert 2007 Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006 Journal of Nuclear Medicine 48 Suppl 1 78S 88S
5. 18F-FDG PET/CT can make a difference in diagnosis and patient care Journal of Nuclear Medicine 48 Suppl 1 28S 35S
6. T. Bunyaviroch R. E. Coleman 2006 PET evaluation of lung cancer Journal of Nuclear Medicine 47 451 469
7. P. Seam M. E. Juweid B. D. Cheson 2007 The role of FDG-PET scans in patients with lymphoma Blood 110 3507 3516
8. W. A. Weber 2005 Use of PET for monitoring cancer therapy and for predicting outcome Journal of Nuclear Medicine 46 983 995
9. P. R. Rich 2003 The molecular machinery of Keilin's respiratory chain Biochemical Society Transactions 31 1095 1105
10. E. Van Schaftingen M. F. Jett L. Hue H. G. Hers 1981 Control of liver 6-phosphofructokinase by fructose 2,6-bisphosphate and other effectors Proceedings of the National Academy of Sciences of the United States of America 78 3483 3486
11. S. Telang A. Yalcinm A. L. Clem R. Bucala A. N. Lane J. W. Eaton 2006 Ras transformation requires metabolic control by 6-phosphofructo-2-kinase Oncogene 25 7225 7234
12. S. C. Huang 2000 Anatomy of SUV. Standardized uptake value Nuclear Medicine and Biology 27 643 646
13. W. A. Weber V. Petersen B. Schmidt L. Tyndale-Hines T. Link C. Peschel 2003 Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use Journal of Clinical Oncology 21 2651 2657
14. 18] fluorodeoxyglucose uptake by positron emission tomography Clinical Cancer Research 6 3837 3844
15. 18F-FDG Journal of Nuclear Medicine 44 1432 1434
16. (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer European Journal of Cancer 43 1392 1398
17. 18F-fluorodeoxyglucose-positron emission tomography Chest 129 393 401
18. 18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool Investigative Radiology 22 360 371
19. 18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma Clinical Cancer Research 6 1279 1287
20. 18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors Journal of Nuclear Medicine 39 810 815
21. M. J. Fulham J. W. Melisi J. Nishimiya A. J. Dwyer G. Di Chiro 1993 Neuroimaging of juvenile pilocytic astrocytomas: an enigma Radiology 189 221 225
22. (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography Journal of Clinical Oncology 20 379 387
23. (18)FDG uptake in oesophageal adenocarcinoma: linking biology and outcome Journal of Cancer Research and Clinical Oncology 134 227 236
24. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression Journal of Nuclear Medicine 45 22 29
25. T. Tohma S. Okazumi H. Makino A. Cho R. Mochiduki K. Shuto 2005 Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer Hepato-Gastroenterology 52 486 490
26. 18 FDG) uptake in melanoma cells: the role of proliferation rate, viability, glucose transporter expression and hexokinase activity Journal of Dermatology 32 316 334
27. 18F]FDG uptake and PCNA, glut-1, and hexokinase-II expressions in cancers and inflammatory lesions of the lung Neoplasia 7 369 379
28. L. F. de Geus-Oei J. H. van Krieken R. P. Aliredjo P. F. Krabbe C. Frielink A. F. Verhagen 2007 Biological correlates of FDG uptake in non-small cell lung cancer Lung Cancer 55 79 87
29. L. Aloj C. Caraco E. Jagoda W. C. Eckelman R. D. Neumann 1999 Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture Cancer Research 59 4709 4714
30. R. A. Gatenby R. J. Gillies 2008 A microenvironmental model of carcinogenesis Nature Reviews Cancer 8 56 61
31. J. W. Kim P. Gao C. V. Dang 2007 Effects of hypoxia on tumor metabolism Cancer and Metastasis Reviews 26 291 298
32. H. Zhang P. Gao R. Fukuda G. Kumar B. Krishnamachary K. I. Zeller 2007 HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity Cancer Cell 11 407 420
33. J. W. Kim I. Tchernyshyov G. L. Semenza C. V. Dang 2006 HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia Cell Metabolism 3 177 185
34. G. L. Semenza P. H. Roth H. M. Fang G. L. Wang 1994 Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1 Journal of Biological Chemistry 269 23757 23763
35. P. Carmeliet Y. Dor J. M. Herbert D. Fukumura K. Brusselmans M. Dewerchin 1998 Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis Nature 394 485 490
36. S. R. Riddle A. Ahmad S. Ahmad S. S. Deeb M. Malkki B. K. Schneider 2000 Hypoxia induces hexokinase II gene expression in human lung cell line A549 American Journal of Physiology. Lung Cellular and Molecular Physiology 278 L407 L416
37. P. Burgman J. A. Odonoghue J. L. Humm C. C. Ling 2001 Hypoxia-induced increase in FDG uptake in MCF7 cells Journal of Nuclear Medicine 42 170 175
38. A. C. Clavo R. S. Brown R. L. Wahl 1995 Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia Journal of Nuclear Medicine 36 1625 1632
39. 18F-FDG PET Journal of Nuclear Medicine 47 1921 1926
40. 18F] fluorodeoxyglucose positron emission tomography imaging Clinical Cancer Research 10 2245 2252
41. (18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression European Journal of Nuclear Medicine and Molecular Imaging 30 695 704
42. H. Shim C. Dolde B. C. Lewis C. S. Wu G. Dang R. A. Jungmann 1997 c-Myc transactivation of LDH-A: implications for tumor metabolism and growth Proceedings of the National Academy of Sciences of the United States of America 94 6658 6663
43. J. W. Kim C. V. Dang 2006 Cancer's molecular sweet tooth and the Warburg effect Cancer Research 66 8927 8930
44. G. L. Semenza 2003 Targeting HIF-1 for cancer therapy Nature Reviews Cancer 3 721 732
45. R. Ravi B. Mookerjee Z. M. Bhujwalla C. H. Sutter D. Artemov Q. Zeng 2000 Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha Genes and Development 14 34 44
46. W. Zundel C. Schindler D. Haas-Kogan A. Koong F. Kaper E. Chen 2000 Loss of PTEN facilitates HIF-1-mediated gene expression Genes and Development 14 391 396
47. H. Zhong K. Chiles D. Feldser E. Laughner C. Hanrahan M. M. Georgescu 2000 Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics Cancer Research 60 1541 1545
48. B. H. Jiang F. Agani A. Passaniti G. L. Semenza 1997 V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression Cancer Research 57 5328 5335
49. R. Fukuda K. Hirota F. Fan Y. D. Jung L. M. Ellis G. L. Semenza 2002 Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells Journal of Biological Chemistry 277 38205 38211
50. E. Laughner P. Taghavi K. Chiles P. C. Mahon G. L. Semenza 2001 HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression Molecular and Cellular Biology 21 3995 4004
51. X. H. Liu A. Kirschenbaum M. Lu S. Yao A. Dosoretz J. F. Holland 2002 Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line Journal of Biological Chemistry 277 50081 50086
52. C. Chen N. Pore A. Behrooz F. Ismail-Beigi A. Maity 2001 Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia Journal of Biological Chemistry 276 9519 9525
53. R. Blum J. Jacob-Hirsch N. Amariglio G. Rechavi Y. Kloog 2005 Ras inhibition in glioblastoma downregulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death Cancer Research 65 999 1006
54. J. Chesney 2006 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis Current Opinion in Clinical Nutrition and Metabolic Care 9 535 539
55. J. Zdychova R. Komers 2005 Emerging role of Akt kinase/protein kinase B signaling in pathophysiology of diabetes and its complications Physiological Research 54 1 16
56. J. E. Thompson C. B. Thompson 2004 Putting the rap on Akt Journal of Clinical Oncology 22 4217 4226
57. D. R. Plas C. B. Thompson 2005 Akt-dependent transformation: there is more to growth than just surviving Oncogene 24 7435 7442
58. N. Majewski V. Nogueira P. Bhaskar P. E. Coy J. E. Skeen K. Gottlob 2004 Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak Molecular Cell 16 819 830
59. J. G. Pastorino J. B. Hoek N. Shulga 2005 Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity Cancer Research 65 10545 10554
60. R. L. Elstrom D. E. Bauer M. Buzzai R. Karnauskas M. H. Harris D. R. Plas 2004 Akt stimulates aerobic glycolysis in cancer cells Cancer Research 64 3892 3899
61. P. K. Majumder P. G. Febbo R. Bikoff R. Berger Q. Xue L. M. McMahon 2004 mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways Nature Medicine 10 594 601
62. S. Matoba J. G. Kang W. D. Patino A. Wragg M. Boehm O. Gavrilova 2006 p53 regulates mitochondrial respiration Science 312 1650 1653
63. H. Kondoh M. E. Lleonart J. Gil J. Wang P. Degan G. Peters 2005 Glycolytic enzymes can modulate cellular life span Cancer Research 65 177 185
64. A. J. Levine Z. Feng T. W. Mak H. You S. Jin 2006 Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways Genes and Development 20 267 275
65. 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro Journal of Nuclear Medicine 47 1525 1530
66. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases Journal of Nuclear Medicine 48 771 775
67. E. Gottlieb I. P. Tomlinson 2005 Mitochondrial tumour suppressors: a genetic and biochemical update Nature Reviews Cancer 5 857 866
68. B. E. Baysal R. E. Ferrell J. E. Willett-Brozick E. C. Lawrence D. Myssiorek A. Bosch 2000 Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma Science 287 848 851
69. S. Niemann U. Muller 2000 Mutations in SDHC cause autosomal dominant paraganglioma, type 3 Nature Genetics 26 268 270
70. I. P. Tomlinson N. A. Alam A. J. Rowan E. Barclay E. E. Jaeger D. Kelsell 2002 Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer Nature Genetics 30 406 410
71. M. A. Selak S. M. Armour E. D. MacKenzie H. Boulahbel D. G. Watson K. D. Mansfield 2005 Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase Cancer Cell 7 77 85
72. S. Bonnet S. L. Archer J. Allalunis-Turner A. Haromy C. Beaulieu R. Thompson 2007 A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth Cancer Cell 11 37 51
73. V. R. Fantin J. St-Pierre P. Leder 2006 Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance Cancer Cell 9 425 434
74. G. V. Thomas C. Tran I. K. Mellinghoff D. S. Welsbie E. Chan B. Fueger 2006 Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer Nature Medicine 12 122 127
75. 18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma Journal of Clinical Oncology 21 3995 4000
76. A. D. Van den Abbeele R. D. Badawi 2002 Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs) European Journal of Cancer 38 Suppl 5 S60 S65
77. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec) European Journal of Cancer 39 2012 2020
78. C. Cullinane D. S. Dorow M. Kansara N. Conus D. Binns R. J. Hicks 2005 An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development Cancer Research 65 9633 9636
79. H. Su C. Bodenstein R. A. Dumont Y. Seimbille S. Dubinett M. E. Phelps 2006 Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors Clinical Cancer Research 12 5659 5667
80. R. A. Gatenby R. J. Gillies 2007 Glycolysis in cancer: a potential target for therapy International Journal of Biochemistry and Cell Biology 39 1358 1366
81. H. Pearson 2007 Cancer patients opt for unapproved drug Nature 446 474 475